RFA and TACE: Equally effective bridging treatments in HCC patients awaiting liver transplantJuly 27, 2022Hepatocellular Carcinoma
First-line pembrolizumab: A promising therapeutic option in advanced HCCJuly 27, 2022Hepatocellular Carcinoma
Advanced HCC: First-line cabozantinib+atezolizumab in select patients shows promise but requires further studyJuly 27, 2022Hepatocellular Carcinoma
SBRT plus TACE better than monotherapy in HCC with portal vein tumor thrombusJune 23, 2022Hepatocellular Carcinoma
Unresectable HCC: Differential efficacy of atezolizumab plus bevacizumab according to hepatic function gradeJune 23, 2022Hepatocellular Carcinoma
Atezolizumab plus bevacizumab offers a better prognosis than lenvatinib in unresectable HCCJune 23, 2022Hepatocellular Carcinoma
HCC with Child-Pugh B cirrhosis: Nivolumab a promising first-line systemic treatment optionJune 23, 2022Hepatocellular Carcinoma
Preoperative ratio of creatinine and cystatin C estimated glomerular filtration rates predicts survival outcomes after hepatic resection for HCCJune 23, 2022Hepatocellular Carcinoma
C reactive protein to albumin ratio predicts survival outcomes in lenvatinib-treated patients with unresectable HCCJune 23, 2022Hepatocellular Carcinoma
Microwave ablation bridges patients with HCC to liver transplantJune 23, 2022Hepatocellular Carcinoma
Pediatric HCC: Histologic subtypes demonstrate distinct clinical patternsJune 23, 2022Hepatocellular Carcinoma
Radiation segmentectomy: A promising treatment option for well-selected patients with HCCJune 23, 2022Hepatocellular Carcinoma
Commentary: Immunotherapy Improves Outcomes in Hepatocellular Cancer, June 2022May 25, 2022Hepatocellular Carcinoma
